小児近視に対する IVMED-85 の有効性
A Randomized, Vehicle-Controlled, Double-Masked Study of the Efficacy and Safety of IVMED-85 Ophthalmic Solution for the Treatment of Pediatric Myopia
To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.
The main aims are:
- Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics
- Assess the safety of a 12-month treatment of IVMED-85
Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.
調査の概要
状態
条件
詳細な説明
This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.
Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.
Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.
The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.
A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Sarah Molokhia, RPH, PhD
- 電話番号:385-229-4491
- メール:smolokhia@iveenamed.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.
- Are 5 to 10 years of age
- Have a minimum body weight of 15.45 kg (34 lbs)
- Willing and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
- Willing and able to comply with clinic visits and study-related procedures
- Able to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
- Willing and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
- Have refractive error as determined by cycloplegic autorefraction: myopia -0.50 D to -7.0 D (spherical equivalent); astigmatism ≤3.00 D; anisometropia ≤2.00 D
- Have BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
- Have corneal thickness between 450 and 680 μm
- Have IOP ≤22 mmHg
- Have axial length ≥20 mm and ≤27 mm
- Willing to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
- Willing to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:IVMED-85 Low Dose
Total subjects n=48, IVMED-85 low dose BID for 12 months |
Eye drop |
|
実験的:IVMED-85 High Dose
Total subjects n=48, IVMED-85 high dose BID for 12 months |
Eye drop |
|
プラセボコンパレーター:Placebo
Total subjects n=48, placebo BID for 12 months |
Eye drop |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Refractive error change from baseline at Month 12
時間枠:Baseline compared to month 12
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12 |
Baseline compared to month 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
時間枠:From screening to the end of treatment at 12 months
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
|
Change in optical biometrics
時間枠:From screening to the end of treatment at 12 months
|
Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits |
From screening to the end of treatment at 12 months
|
|
Refractive error at non-final study visits
時間枠:From screening to the end of treatment at 12 months
|
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12 |
From screening to the end of treatment at 12 months
|
|
Sub foveal choroidal thickness
時間枠:From screening to the end of treatment at 12 months
|
Change from baseline in sub foveal choroidal thickness in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
|
Accommodative amplitude in the spherical equivalent
時間枠:From screening to the end of treatment at 12 months
|
Change from baseline in accommodative amplitude in the SE at Month 12 |
From screening to the end of treatment at 12 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression of high myopia
時間枠:From screening to the end of treatment at 12 months
|
Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12 |
From screening to the end of treatment at 12 months
|
|
Progression of prospectively identified progressive myopia
時間枠:From screening to the end of treatment at 12 months
|
Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records |
From screening to the end of treatment at 12 months
|
協力者と研究者
捜査官
- スタディチェア:Bala Ambati、iVeena Delivery Systems, Inc.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。